Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT06110793 | A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2026 |
| clinicaltrials |
| NCT03716180 | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | active not recruiting | Phase 1 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04040569 | A Phase I Dose Escalation Study of Single Fraction Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer | active not recruiting | Phase 1 | 45 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT02484404 | Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | active not recruiting | Phase 1 / Phase 2 | 268 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT01872260 | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 259 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 18, 2026 | clinicaltrials |
| NCT06746688 | A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer. | active not recruiting | Phase 1 | 40 | ExpreS2ion BiotechnologiesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT02453620 | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | active not recruiting | Phase 1 | 190 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT05809752 | A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) | active not recruiting | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05262400 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 235 | PfizerINDUSTRY | 9 | Sep 14, 2026 | clinicaltrials |
| NCT05870579 | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | active not recruiting | Phase 1 | 28 | Novartis PharmaceuticalsINDUSTRY | 7 | Sep 11, 2026 | clinicaltrials |
| NCT06247995 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.(NeoB-Cap1) | active not recruiting | Phase 1 / Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 11, 2026 | clinicaltrials |
| NCT01351909 | Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03964532 | TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06966453 | A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 74 | PfizerINDUSTRY | 9 | Sep 9, 2026 | clinicaltrials |
| NCT03006172 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | active not recruiting | Phase 1 | 200 | Genentech, Inc.INDUSTRY | 5 | Sep 8, 2026 | clinicaltrials |
| NCT03939897 | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02208375 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | active not recruiting | Phase 1 | 159 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03317405 | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | active not recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05548127 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | active not recruiting | Phase 1 / Phase 2 | 37 | PfizerINDUSTRY | 4 | Sep 2, 2026 | clinicaltrials |
| NCT03401385 | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | active not recruiting | Phase 1 | 890 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT05460273 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | active not recruiting | Phase 1 / Phase 2 | 119 | AstraZenecaINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04427293 | Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 | 12 | University of Illinois at ChicagoOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06475937 | A Study of DM001 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 128 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02685332 | Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA | active not recruiting | Phase 1 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04288089 | A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer | active not recruiting | Phase 1 | 31 | Eisai Inc.INDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT06299124 | A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors | active not recruiting | Phase 1 | 40 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06577987 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | active not recruiting | Phase 1 | 220 | Circle PharmaINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT01327781 | Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07610148 | A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants | active not recruiting | Phase 1 | 21 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06590857 | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.(TRACY-1) | active not recruiting | Phase 1 / Phase 2 | 16 | RayzeBio, Inc.INDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT04360941 | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer(PAveMenT) | active not recruiting | Phase 1 | 45 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | active not recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03959891 | AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | active not recruiting | Phase 1 | 77 | Massachusetts General HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03616587 | Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.(SERENA-1) | active not recruiting | Phase 1 | 396 | AstraZenecaINDUSTRY | 3 | Aug 18, 2026 | clinicaltrials |
| NCT05340673 | Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer | active not recruiting | Phase 1 | 208 | City of Hope Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03332797 | A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer | active not recruiting | Phase 1 | 181 | Genentech, Inc.INDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT03858322 | 'ADVANCE' (A Pilot Trial) | active not recruiting | Phase 1 | 41 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials